First dengue vaccination program in the Americas starts in Paraná State of Brazil

0
1121

image002

Sanofi Pasteur, the vaccines division of Sanofi, announced today that Paraná State has launched the first public dengue immunization program in the Americas, targeting vaccination of 500,000 of the state’s residents this year. In addition, Brazilians can also get access to dengue vaccination in private healthcare clinics around the country.

Paraná State is located in the South of Brazil and is the sixth most densely-populated state with an estimated 10,444,526 residents; over 85% of whom live in urban settings. In the last few years, dengue incidence in the state has increased three fold from 2013 to 2015. The public program announced today will target individuals living in highly urban centers of the State, where dengue continues to bring significant human and economic burden every year.

“The world finally has a clinical prevention tool against dengue that has been shown to be efficacious in the Brazilian population, as well as endorsed by the WHO,” says, Michele Caputo Neto, Minister of Health for Paraná State. “With our strong disease surveillance and community mobilization infrastructure in Paraná State, we are well-positioned to introduce the first public dengue immunization program in the Americas to significantly reduce our disease burden.

The safety, efficacy and public health value of Sanofi Pasteur’s dengue vaccine has been independently endorsed by the Strategic Advisory Group of Experts on Immunization (SAGE) to the World Health Organization (WHO). This positive WHO recommendation for use of the vaccine in endemic countries like Brazil as part of integrated dengue prevention efforts is based on extensive clinical documentation for the vaccine involving over 40,000 individuals from 15 countries around the world. In these studies, Dengvaxia® demonstrated consistent safety and efficacy across a diverse ethnic, geographic and socio-economic population.

Dengue continues to represent a growing public health threat for Brazilians with disruptive outbreaks that often paralyze local healthcare systems. In 2015, over 1.6 million Brazilians reported being ill with dengue. Almost 60% of the dengue cases in the country occur in individuals 10 to 39 years of age, which falls within the approved age indication 9 to 45 years for Dengvaxia® in Brazil. This pre-adolescent to adult population represents a highly mobile and social segment of the community who contribute significantly to spread of the infection.

About Sanofi Pasteur Dengue Vaccine

In addition to Brazil, Sanofi Pasteur Dengue Vaccine is also registered in Mexico, Philippines, El Salvador and Costa Rica to date. Regulatory review processes for Dengue Vaccine are continuing in other countries where dengue is a public health priority.

Sanofi Pasteur’s vaccine is the culmination of over two decades of scientific innovation and collaboration, as well as 25 clinical studies in 15 countries around the world. Over 40,000 volunteers participated in the Sanofi Pasteur dengue vaccine clinical study program (phase I, II and III), of whom, 29,000 volunteers received the vaccine.

A summary of the efficacy documentation on Dengvaxia® for the study population 9 years and older population was published in The New England Journal of Medicine on July 27th 2015. These findings affirm the vaccine’s consistent efficacy in reducing dengue due to all four serotypes in two-thirds of the study participants 9 years and older and also documents the ability of the vaccine to prevent 8 out of 10 hospitalizations and up to 93% of severe dengue cases in this age group during the 25 month follow-up phase of the studies.

An integrated safety analysis was recently published showing that Dengvaxia® had a satisfactory safety profile comparable to placebo during the late stage clinical study program involving around 30,000 participants from 15 countries. In addition, the results of this analysis documented that the vaccine provided beneficial protection against hospitalization due to dengue and severe dengue for up to 4 years post dose 1 of vaccination compared to placebo in the study population 9 years and older.

Sanofi Pasteur Dengue Vaccine is the first vaccine licensed for the prevention of dengue in the world. The vaccine is supplied from a dedicated production site in France.

Additional information about Sanofi Pasteur’s dengue vaccine is available on the web at www.dengue.info.